Autopsy report · NCT04220892
Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
Cause of deathSafety, also drug or device supply
“One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab + abemaciclib study arm is removed due to toxicity seen in other trials.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Early Phase 1
- Sponsor
- Jose Carrillo
- Sponsor type
- University, hospital or other
- Conditions
- High Grade Glioma
- Interventions
- Pembrolizumab; Pemetrexed; Abemaciclib
- Participants
- 0
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Panobinostat/Velcade in Multiple Myeloma
“This study was terminated because the drug company stopped making the study drug” - Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
“Manufacturer is no longer making the drug.” - CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
“Study drug no longer available” - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
“The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.” - A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
“Trial was terminated for business reasons. There has been no change in the benefit/risk profile of ofatumumab.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.